Peter Wirth joined our Board in 2017 and serves as Chair of the Compensation Committee and is a member of the Audit Committee.
Mr. Wirth is a seasoned executive that brings to our Board expertise in corporate governance, corporate strategy, product development, business development and legal issues relating to the operation of a global pharmaceutical company.
In addition to serving on our Board, he has served as Chairman of the Board of Syros Pharmaceuticals, a Nasdaq-listed biopharmaceutical company, since 2017. He has also served on other public company boards, including as Chairman of FORMA Therapeutics Holdings LLC, a Nasdaq-listed small molecule drug discovery company, from 2012 until its acquisition by Novo Nordisk A/S in October 2022.
Mr. Wirth has significant management and leadership experience from his executive roles at a number of biopharmaceutical companies as well as deep experience with respect to legal issues facing biopharmaceutical companies from his decades of law firm experience. For example, he co-founded and served as President and Director of Lysosomal Therapeutics, Inc., a biopharmaceutical company focused on small molecule research, from 2011 to 2014. Prior to that, he served in various senior executive roles at Genzyme Corporation from 1996 until its acquisition by Sanofi-Aventis SA in 2011, most recently as Executive Vice President, Legal and Corporate Development, Chief Risk Officer, and Corporate Secretary. He previously spent over 20 years as Partner at Palmer & Dodge LLP, where he was head of the firm’s biotechnology practice group and served as outside general counsel for Genzyme and a number of other biotechnology companies.
Mr. Wirth received a J.D. from Harvard Law School and a B.A. in Political Science from the University of Wisconsin at Madison.